Belite Bio (BLTE) vs Supernus (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Belite Bio (BLTE) has outperformed Supernus (SUPN) over the past year, gaining 5.7% versus a loss of 36.9%. Supernus is the larger company by market cap ($5.94 billion vs $5.17 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | SUPN |
|---|---|---|
| Share price | $127.38 | $28.61 |
| Market cap | $5.17B | $5.94B |
| 1-day change | -15.65% | +0.92% |
| YTD return | -20.37% | -42.43% |
| 1-year return | +5.66% | -36.87% |
| 5-year return | — | -6.53% |
| Forward P/E | — | 7.15 |
| EPS (TTM) | $-2.84 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | $-77.61M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $200.00 | $42.81 |
| 52-week low | $115.41 | $25.92 |
| Distance from 52-week high | -36.31% | -33.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.92% | +89.23% |
| Average volume | 195.65K | 2.77M |
| Shares outstanding | 40.61M | 207.72M |
| Employees | 41 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed SUPN by 42.5 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Supernus
SUPN stock →Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
BLTE vs SUPN FAQ
Which is bigger, Belite Bio or Supernus?
Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.17B for Belite Bio (BLTE).
Which stock has performed better over the past year, BLTE or SUPN?
BLTE returned +5.66% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Supernus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.